Skip to main content

Featured

TSX Down About 8% in a Week: Should You Tax-Loss Sell Before the Dec. 30 Deadline?

  Canadian Money Brief • Year-End Tax Planning • Nov. 21, 2026 If you opened your brokerage app this week and winced, you are not alone. The S&P/TSX composite closed Friday at 33,189.85, down 838.88 points (about 2.5%) on the day, according to The Canadian Press. A week earlier it closed at 36,105.90, so the index has shed roughly 8% in five trading days. South of the border, the AP reported the S&P 500 fell 3.7% on Friday for its worst weekly loss in more than 18 months, while the Nasdaq slid into negative territory for the year. Painful? Yes. But if you hold investments in a non-registered account, a falling market also hands you a tax tool: tax-loss selling . Used carefully, it can turn a paper loss into a lower tax bill. Used carelessly, it can leave you with no tax benefit at all, or with a portfolio that no longer matches your plan. Here is how it works and what to check before the deadline. THE DEADLINE: Wednesday, Dec. 30, 2026 is the last trading day for most Cana...

article

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Comments